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Background: It is clear that genetic variations in the fat mass and obesity-associated (FTO) gene affect body mass
index and the risk of obesity. Given the mounting evidence showing a positive association between obesity and
pancreatic cancer, this study aimed to investigate the relation between variants in the FTO gene, obesity and
pancreatic cancer risk.
Methods: We conducted a hospital-based case–control study in Japan to investigate whether genetic variations in
the FTO gene were associated with pancreatic cancer risk. We genotyped rs9939609 in the FTO gene of 360 cases
and 400 control subjects. An unconditional logistic model was used to estimate the odds ratio (OR) and 95%
confidence interval (CI) for the association between rs9939609 and pancreatic cancer risk.
Results: The minor allele frequency of rs9939609 was 0.18 among control subjects. BMI was not associated with
pancreatic cancer risk. Compared with individuals with the common homozygous TT genotype, those with the
heterozygous TA genotype and the minor homozygous AA genotype had a 48% (OR=1.48; 95%CI: 1.07–2.04), and
66% increased risk (OR=1.66; 95%CI: 0.70–3.90), respectively, of pancreatic cancer after adjustment for sex, age, body
mass index, cigarette smoking and history of diabetes. The per-allele OR was 1.41 (95%CI: 1.07–1.85). There were no
significant interactions between TA/AA genotypes and body mass index.
Conclusions: Our findings indicate that rs9939609 in the FTO gene is associated with pancreatic cancer risk in
Japanese subjects, possibly through a mechanism that is independent of obesity. Further investigation and
replication of our results is required in other independent samples.
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In 2010, approximately 28,000 Japanese subjects died
from pancreatic cancer, making it the fifth leading cause
of cancer deaths in Japan [1]. Despite extensive research
efforts, the etiology of pancreatic cancer remains poorly
understood. Cigarette smoking and long-standing type II
diabetes are two well-established risk factors, based on
consistent findings from epidemiologic studies [2,3]. In
addition, being overweight and obese have been impli-
cated in the development of pancreatic cancer [4], with* Correspondence: kikuchis@aichi-med-u.ac.jp
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reproduction in any medium, provided the orstatistically significant, positive associations observed in
large cohort studies conducted in Western countries
[5-7], and corroborated in at least four meta-analyses
[8-11] and three pooled analyses [12-14]. The positive
association between body mass index (BMI) and pancre-
atic cancer, however, has not been clearly observed in
Asian populations. To date, four cohort studies have ex-
amined the association between BMI and pancreatic
cancer in Asians, but the results have been inconsistent
and inconclusive [15-18].
Recently, genome-wide association (GWA) studies
have identified at least 30 loci that affect BMI and the. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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http://www.biomedcentral.com/1471-2407/13/337risk of obesity [19]. Among these loci, the fat mass and
obesity-associated (FTO) gene, which was first identified
in a GWA study of diabetes in 2007 [20], has the stron-
gest influence on BMI and obesity. Rs9939609, located
in the first intron of the FTO gene, was found to be as-
sociated with both BMI and type II diabetes in subse-
quent GWA studies in diverse populations [21-23]. The
association of rs9939609 with various traits, including
hip circumference, energy intake and total mortality has
also been studied [24-26]. In addition, rs9939609 geno-
types have been linked with the risk of prostate, breast
and endometrial cancers [27-29]. The association be-
tween genetic variations in the FTO gene and the risk of
pancreatic cancer, however, is not clear. Of the three
studies that examined this association, only one case–
control study, conducted at the MD Anderson Cancer
Center in the United States, reported that the minor A
allele of FTO, rs9939609, was associated with an in-
creased risk of pancreatic cancer among overweight sub-
jects [30]. Another two studies examined rs8050136 of
the FTO gene, with one study reporting a positive asso-
ciation [31], and the other no association [32].
Given the mounting evidence showing a positive asso-
ciation between obesity and pancreatic cancer, we hy-
pothesized that variants in the FTO gene may be
associated with pancreatic cancer risk through effects on
obesity or other mechanisms. In a search of the litera-
ture for obesity-related genetic variants, we found that
FTO rs9939609 was the most widely studied single nu-
cleotide polymorphism (SNP), and has been found to
exert strong effects on BMI, as well as diabetes. Further-
more, it showed strong linkage disequilibrium with other
SNPs in the FTO gene, such as rs8050135 and
rs17817449 [22]. We therefore investigated the associ-
ation between FTO rs9939609 and pancreatic cancer
risk in a case–control study in Japan.
Methods
Study subjects
Our study is an ongoing hospital-based case–control
study focusing on the role of genetic polymorphisms
and gene-environment interaction in pancreatic cancer.
For the present analysis, eligible cases were patients aged
older than 20 years, who were newly diagnosed with
pancreatic cancer in five hospitals located in central,
north and Tokyo metropolitan areas from April 1, 2010
through May 15, 2012. The diagnosis of pancreatic can-
cer was based on imaging modalities or pathologic re-
ports. The response rate among cases was 85% (441/
516) as of July 1, 2012. Almost all of the cases were
approached within a week after the diagnosis of pancre-
atic cancer, and very few cases died before they were in-
vited to participate in our study. During the same
period, we recruited control subjects with no diagnosisof cancer from inpatients and outpatients from the par-
ticipating hospitals where the cases were enrolled, as
well as relatives of inpatients, and individuals undergo-
ing a medical checkup in one of the participating hospi-
tals. Control subjects were eligible if they were more
than 20 years old and had no prior cancer diagnoses. Re-
cruitment of controls was accomplished by approaching
eligible participants in the hospitals who satisfied the
study requirements, and the response rate was 98%
(525/534). Control subjects had a variety of diseases,
such as anemia, gastric ulcer, and irritable bowel syn-
drome. Control subjects were matched with case pa-
tients according to sex and age (within 10-year
categories). As a result, data from 360 case patients and
400 control subjects were included in the present
analysis.
All subjects provided written, informed consent. This
study was approved by the ethical board of Aichi Medical
University (Nagakute, Japan), the Institutional Review
Board (IRB) of Cancer Institute Hospital (Tokyo,
Japan), the IRB of Kanagawa Cancer Center Hospital
(Kanagawa, Japan), the IRB of Tokyo Metropolitan
Komagome Hospital (Tokyo, Japan), and the IRB of
Sapporo Medical University (Sapporo, Japan).Data collection
Study subjects were asked to fill out a self-administered
questionnaire including information on demographic
characteristics, medical history, and lifestyle factors, such
as cigarette smoking, alcohol consumption and dietary
intake. For body weight, data on usual weight over the
year prior to study entry as well as weight at age 20 were
reported by the study participants. For current or former
smokers, we collected detailed data on smoking expos-
ure, including smoking status (never, former, or current
smokers), average number of cigarettes smoked per day,
age at starting and quitting, and duration of smoking.
For subjects with type II diabetes, we recorded the age
at diagnosis. In addition to the questionnaire survey, all
consenting participants provided a 7-mL venous blood
sample. Genomic DNA was extracted from peripheral
lymphocytes at SRL Hachioji Laboratory and then stored
at -30°C at the Department of Public Health, Aichi Med-
ical University.Genotyping assays
Genotyping was performed using the Taqman SNP
Genotyping Assay (Applied Biosystems, Foster City, CA,
USA) at the laboratory of Aichi Cancer Center Research
Institute, Nagoya, Japan. Laboratory staff were blinded
to case or control status. Four quality control samples
were included in each assay, and the successful genotyp-
ing rate was 100%.
Table 1 Association between variations in the fat mass
and obesity-associated gene and pancreatic cancer risk:
a case–control study in Japan




<50 12 (3.3) 19 (4.8)
50-59 44 (12.2) 79 (19.8)
60-69 141 (39.2) 170 (42.5)
70-79 138 (38.3) 115 (28.8)
≥80 25 (6.9) 17 (4.3)
Sex Matching
factor
Female 215 (59.7) 226 (56.5)
Male 145 (40.3) 174 (43.5)
Body mass index
(kg/m2)
<25 278 (77.2) 312 (78.0) 1.00
25.0-29.9 64 (17.8) 75 (18.7) 0.96 (0.65-1.43)
≥30 16 (4.4) 12 (3.0) 1.21 (0.53-2.77)
Unknown 2 (0.6) 1(0.3) -
Smoking status
Non-smokers 145 (40.2) 202 (50.5) 1.00
Former smokers 119 (33.1) 140 (35.0) 1.23 (0.82-1.85)
Current Smokers 96 (26.7) 58 (14.5) 2.86 (1.79-4.57)
History of diabetes
No 269 (74.7) 362 (90.5) 1.00
Yes 87 (24.2) 35 (8.7) 2.94 (1.90-4.57)
Unknown 4 (1.1) 3 (0.8) -
OR: odds ratio; CI: confidence interval.
OR was adjusted for sex, age, smoking status and history of diabetes.










TT 213 271 1.00 1.00
TA 133 116 1.49 (1.09-2.03) 1.48 (1.07-2.04)
AA 14 13 1.49 (0.67-3.29) 1.66 (0.70-3.90)
OR: odds ratio ; CI: confidence interval.
Multivariable adjusted OR: adjusted for age, sex, body mass index, cigarette
smoking and history of diabetes.
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Case–control differences in selected demographic char-
acteristics and risk factors were evaluated using t tests
(for continuous variables) and Chi-square tests (for cat-
egorical variables). A chi-square test was used to test
genotype frequencies in control subjects for Hardy-
Weinberg equilibrium (HWE) by comparing observed
genotype frequencies with those expected under HWE.
A co-dominant genomic model was assumed for SNP ef-
fects. Unconditional logistic regression methods were
used to estimate odds ratios (ORs) and 95% confidence
intervals (CIs) for the association between rs9939609 ge-
notypes and pancreatic cancer risk. Homozygous carriers
of the common FTO rs9939609 T allele served as the
reference group. All analyses were adjusted for age (con-
tinuous), sex (male or female), BMI (<20, 20–22.4, 22.5-
24.9, ≥25.0), history of diabetes (yes or no), and cigarette
smoking (current, former, never smokers). ORs were also
estimated for the variant allele on the basis of a log-
additive model. The interaction of genotype-BMI and
genotype-history of diabetes with respect to pancreatic
cancer risk was assessed using the likelihood ratio test.
Because recent-onset diabetes may result from pancre-
atic cancer, we performed an analysis excluding cases
who had onset of diabetes within 2 years prior to the
diagnosis of pancreatic cancer.
All P-values were two-sided, with P<0.05 indicating
statistical significance. All statistical analyses were
performed using SAS 9.2 (SAS Institute, Inc., Cary, NC,
USA).
Results
The distribution of genotypes among control subjects
did not deviate from the Hardy-Weinberg equilibrium
(P=0.94). The minor allele frequency (MAF) was 0.18
among control subjects. Table 1 summarizes the charac-
teristics of cases and controls. Both groups had a similar
distribution of sex and 10-year age groups. The mean
age was 65.1±8.1 years for cases, and 58.5±9.1 years for
controls. Cases were more likely to be current smokers
and have a history of diabetes compared with controls.
Current smokers had an approximately 2.9-fold increased
risk of pancreatic cancer compared with nonsmokers,
after adjustment for age, sex, BMI, and history of diabetes
(OR=2.86; 95%CI: 1.79-4.57). Individuals who had a BMI
of 30 or more had a 1.21-fold increased risk, but the asso-
ciation was not statistically significant. Similar results were
obtained in an additional analysis in which BMI at age 20
was used (data not shown). Risk of pancreatic cancer was
significantly increased among subjects reporting a history
of diabetes (OR=2.94; 95%CI: 1.90-4.57). The significant,
positive association remained after excluding pancreatic
cancer cases with recent-onset diabetes (OR=1.92; 95%CI:
1.20–3.08). Among control subjects, the mean BMI was22.7±3.1 for the TT genotype, 23.2±3.3 for the TA geno-
type, and 21.1±2.9 for the AA genotype.
Table 2 shows the association between variants in the
FTO gene (rs9939609) and pancreatic cancer risk. Com-
pared with individuals with the TT genotype, the multi-
variate adjusted OR for developing pancreatic cancer
was 1.48 (95%CI: 1.07–2.04) among those with the TA
Table 4 Joint associations of the FTO rs 9939609 and










TT No 163/243 1.00 1.00
TA/AA No 106/119 1.38 (0.99-1.93) 1.41 (1.00-1.98)
TT Yes 34/26 1.76 (1.01-3.07) 1.70 (0.96-3.00)
TA/AA Yes 24/8 4.03 (1.75-9.24) 3.70 (1.59-8.63)
P for
interaction=0.28
Cases were excluded if the onset of diabetes was within 2 years prior to the
diagnosis of pancreatic cancer.
Multivariable OR: adjusted for age, sex, body mass index, and
cigarette smoking.
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the AA genotype. Under the dominant model, the OR
was 1.49 (95%CI: 1.09–2.05) among carriers of the TA/
AA genotype. Under the log-additive model, each add-
itional copy of minor allele A was associated with a 1.4-
fold increased risk of pancreatic cancer (OR=1.41, 95%
CI: 1.07–1.85).
We found no significant interaction between FTO
rs9939609 and BMI (Table 3). Individuals with both a
TA/AA genotype and a history of diabetes had a 3.7-fold
increased risk of pancreatic cancer compared with those
with a TT genotype and no history of diabetes (Table 4),
but a test for the interaction was not statistically
significant.Discussion
This was a hospital-based case–control study in Japan to
investigate whether genetic variations in the FTO gene
were associated with pancreatic cancer risk. The main
findings of our study were: 1) individuals with the FTO
rs9939609 TA genotype had a significant 1.5-fold in-
creased risk of pancreatic cancer compared with those
with the TT genotype; and 2) a combination of the FTO
rs9939609 TA/AA genotype and a history of diabetes
significantly increased the pancreatic cancer risk, with
an OR of 3.70 (95%CI: 1.59–8.63).
We found that obesity, defined as a BMI of 30 or
more, was associated with 1.2-fold increased risk of pan-
creatic cancer, but this association was not statistically
significant. In contrast to evidence of a positive associ-
ation between obesity and pancreatic cancer in Western
countries, available data on the role of obesity in pancre-
atic cancer in Japanese are inconclusive. There have
been no prospective studies that have observed a clear,
dose–response relation between baseline BMI and pan-
creatic cancer risk in the Japanese population [15,16].
Given that less than 5% of the subjects were obese in
this study, it might be difficult to observe significant as-
sociations. The small percentage of obese people may be
the main reason for the inconclusive results on BMI andTable 3 Joint associations of the FTO rs9939609 and BMI







TT <25 166/220 1.00 1.00
TA/AA <25 112/92 1.69 (1.20-2.40) 1.68 (1.18-2.41)
TT ≥25 45/51 1.29 (0.81-2.04) 1.20 (0.75-1.94)
TA/AA ≥25 35/36 1.35 (0.81-2.25) 1.21 (0.71-2.07)
P for
interaction=0.29
Multivariable OR: adjusted for age, sex, cigarette smoking and history
of diabetes.pancreatic cancer in Asians, including Japanese [15-18].
In addition, differences in body fat distribution, in gen-
etic predisposition to obesity and in lifestyle factors be-
tween Caucasians and Asians may contribute to the
inconsistent results on BMI and pancreatic cancer risk
in Asian populations [33,34].
Because of the positive association between obesity
and pancreatic cancer in Caucasians and the plausible
mechanisms, several research groups have hypothesized
that variants in obesity-related genes might be associated
with pancreatic cancer risk. The association between
rs9939609 in the FTO gene was reported in one previ-
ous hospital–based case–control study conducted at the
MD Anderson Cancer Center, Texas, USA [30]. Of the
15 obesity- and diabetes-associated genotypes in the
FTO gene, rs9939609 was found to be positively associ-
ated with pancreatic cancer risk in persons who were
overweight, whereas no increased risk was observed in
persons who had a BMI of less than 25 kg/m2 [30]. In
contrast, our study showed a significant, positive associ-
ation between rs9939609 TA/AA genotype and pancre-
atic cancer risk in individuals with a BMI of less than 25
kg/m2. We consider that the difference in minor allele
frequency (MAF) may be the main reason, given the fact
that the MAF was 18% in our study, much lower than
the 38% in the MD Anderson Cancer Center case–control
study. The possible differences in selection of cases and
controls, patterns of linkage disequilibrium and effects of
gene-gene interactions may also account for the inconsist-
ent findings. In addition to rs9939609, rs8050136 in the
FTO gene was found to be associated with pancreatic
cancer risk in individuals of European ancestry [31];
however, no association was noted in another case–
control study [32].
In our study, FTO rs9939609 genotypes were associ-
ated with pancreatic cancer risk. However, the mean
BMI did not differ among rs9939609 genotypes for con-
trol subjects, and no significant interaction was observed
between rs9939609 TA/AA genotypes and BMI with
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positive association observed between rs9939609 geno-
types and pancreatic cancer risk may be driven by a
mechanism other than adiposity. Diabetes, a well-
established risk factor for pancreatic cancer, is a possible
candidate. There is evidence suggesting that Asian
people are more susceptible to insulin resistance at a
lesser degree of obesity than Caucasians [33,34]. Besides
its close association with adiposity, FTO has been shown
to be associated with susceptibility to type II diabetes
[21,22]. We found that individuals with a TA/AA geno-
type and a history of diabetes were at a 3.7-fold in-
creased risk of pancreatic cancer. However, a test for the
interaction was not statistically significant. Another pos-
sibility is that FTO is just a proxy of as yet unidentified
causal variants, and it is those variants that exert their
effects on rs9939609 and influence pancreatic cancer
risk. Given that the function of the FTO gene is largely
unknown, further studies are needed to comprehensively
evaluate multiple SNPs in the FTO gene and elucidate
the mechanisms by which FTO rs9939609 influences
pancreatic cancer risk.
Our study has several limitations. First, it is well-
known that two significant issues, namely selection bias
and recall bias, plague case–control studies. Our results
might have been biased if hospital controls did not rep-
resent the same population from which the cases were
derived. However, the allele frequencies observed among
control subjects in our study were similar to those
reported in the studies of Asian populations [22]. In par-
ticular, the MAF of FTO rs9939609 was 18% in our con-
trol subjects, which is very close to that reported from a
sample of 100 Japanese included in the HapMap project.
Moreover, the risk estimates for current smokers and in-
dividuals with a history of diabetes were comparable to
those estimated from cohort or population-based case–
control studies [2,3], providing indirect evidence that se-
lection bias might not be a serious concern in our study.
Second, as for recall bias, while the analysis of the asso-
ciation between pancreatic cancer and BMI based on
self-reported weight and height might be affected by re-
call bias, the association with the obesity-related geno-
type was not. Third, although our study included a
relatively large sample size compared with previous
studies conducted in Japan, the sample size may not
have been large enough to detect significant gene-
environment interactions in subgroups. Finally, it is
possible that the results could represent a chance associ-
ation and therefore replication in other independent
samples is required. Despite these limitations, there are
several advantages of the hospital-based design adopted
in our study, including rapid case ascertainment, a high
response rate from both cases and controls, and high
quality genotyping.Conclusion
Our findings indicate that rs9939609 in the FTO gene is
associated with pancreatic cancer risk in Japanese subjects,
possibly through a mechanism that is independent of
obesity. Because of the limited statistical power, our results
need replication in other independent samples. The fast-
increasing prevalence of overweight/obesity and type II
diabetes in Asians provides a good opportunity to further
address this association and its underlying mechanisms.
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